

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 September 2006 (21.09.2006)

PCT

(10) International Publication Number  
**WO 2006/099396 A2**

(51) International Patent Classification:  
**A61K 31/19** (2006.01)

(21) International Application Number:  
PCT/US2006/009078

(22) International Filing Date: 13 March 2006 (13.03.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/660,893 11 March 2005 (11.03.2005) US

(71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF COLORADO** [US/US]; 201 Regent Administrative Center, 3 Sys, Boulder, Colorado 80309 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WITTA, Samir, E.** [US/US]; 1197 S. Monaco Pkwy, Denver, Colorado 80540 (US). **BUNN, Paul, A., JR.** [US/US]; 630 Sundown Lane, Evergreen, Colorado 80439 (US). **DRABKIN, Harry, A.** [US/US]; 3886 S. Magnolia Way, Denver, Colorado 80237 (US). **GEMMILL, Robert, M.** [US/US]; 7177 E. Costilla Drive, Centennial, Colorado 80112 (US). **CHAN, Daniel** [US/US]; 3691 South Quebec Street, Denver, Colorado 80237 (US).

(74) Agents: **SEBOR, Angela, Dallas** et al.; SHERIDAN ROSS P.C., 1560 Broadway, Suite 1200, Denver, Colorado 80202-5141 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: HISTONE DEACETYLASE INHIBITORS SENSITIZE CANCER CELLS TO EPIDERMAL GROWTH FACTOR INHIBITORS



A



B

(57) Abstract: Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer.

WO 2006/099396 A2



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## HISTONE DEACETYLASE INHIBITORS SENSITIZE CANCER CELLS TO EPIDERMAL GROWTH FACTOR INHIBITORS

### Field of the Invention

5           This application generally relates to the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer.

### Background of the Invention

10           Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the world. While chemotherapy has produced modest survival benefits in advanced stages, standard two-drug combinations generate considerable toxicity and require intravenous administration. Progress in the field of lung cancer biology led to the development of small molecule inhibitors of target proteins involved in the proliferation, apoptosis and angiogenesis. Targeted therapy agents such as imatinib and trastuzumab produced  
15           consistent survival benefit in chronic myeloid leukemia, gastrointestinal stromal tumors (GIST) and breast cancers that overexpress the target proteins. The epidermal growth factor receptor (EGFR) superfamily, including the four distinct receptors EGFR/erbB-1, HER2/erbB-2, HER3/erbB-3, and HER4/erbB-4, was early identified as a potential therapeutic target in solid tumors. After ligand binding, these receptors homo- and  
20           heterodimerize, and the tyrosine-kinase domain is activated, initiating a cascade of events implicated in the development and progression of cancer through effects on cell-cycle progression, apoptosis, angiogenesis, and metastasis. EGFR is overexpressed in many human epithelial malignancies, including NSCLC.

          Given the biological importance of the EGFR molecular network in carcinomas,  
25           several molecules were synthesized to inhibit the tyrosine kinase domain of EGFR. Among the most promising of these new drugs are gefitinib (ZD 1839, IRESSA<sup>®</sup>, AstraZeneca, UK), and erlotinib (OSI 774, TARCEVA<sup>®</sup>, Genentech, USA). Both are orally active, selective EGFR tyrosine-kinase inhibitors (EGFR-TKI) that demonstrated antitumor activity against a variety of human cancer cell lines expressing EGFR. Likewise, both have well  
30           documented activity as single agents in phase I studies including chemotherapy resistant NSCLC patients who had response rates of about 10%. Activity was confirmed in large phase II trials showing response rates of 19-26% in previously untreated, advanced NSCLC patients, and 12-18% in patients who had failed one or more prior chemotherapy

combinations. More recently, a survival benefit with erlotinib as a second or third line therapy was reported in a trial performed by the National Cancer Institute Canada.

In phase II trials with gefitinib, no correlation was detected between EGFR protein expression and response to therapy. Patients with squamous cell carcinomas had lower response rates compared to patients with adenocarcinoma despite their higher rates of EGFR expression. Recent reports showed that specific missense and deletion mutations in the tyrosine kinase domain of the EGFR gene are significantly associated with gefitinib sensitivity. However, while objective response has been reported in up to 18% and symptomatic improvement in 40% of the unselected gefitinib treated NSCLC patients, the low frequency of these mutations in unselected US patients suggest that other mechanisms are also involved in the response to gefitinib. EGFR interacts with cell adhesion molecules including the integrins and E-cadherin (E-cad, CDH1). E-cad is a calcium-dependent epithelial cell adhesion molecule that plays an important role in tumor invasiveness and metastatic potential. Reduced E-cad expression is associated with tumor cell dedifferentiation, advanced stage and reduced survival in patients with NSCLC. E-cad-mediated cell adhesion requires intracellular attachment to the actin cytoskeleton through the interaction with  $\beta$ -,  $\alpha$ - and  $\gamma$ -catenin. Activation of EGFR leads to a loss of the membranous localization and proteosomal degradation of E-cad and  $\beta$ -catenin. E-cad is also involved in regulation of EGFR and its downstream targets. E-cad inhibits ligand-dependent activation of EGFR and other RTKs. On the other hand, E-cad action on neighboring cells leads to PI 3-kinase-dependent activation of AKT and the rapid translocation of AKT to the nucleus. E-cad also stimulates the MAPK pathway through the ligand-independent activation of EGFR. At the transcriptional level, *E-cad* expression is regulated by the wnt/ $\beta$ -catenin signaling, the EGFR signaling via ERK or caveolin, the transcription factor AP-2, the basic helix-loop-helix E12/E47 factor, and by several zinc finger transcription factors including the Slug/Snail family, SIP1 and TF8 (ZEB-1, ZFHX1A, AREB6,  $\delta$ EF1). These zinc-finger transcription factors regulate the expression of several genes via the interaction with two 5'-CACCTG (E-box) promoter sequences. This regulation is facilitated by the interaction with CtBP, which recruits histone deacetylases (HDAC) leading to chromatin condensation and gene silencing. Inhibiting HDAC using trichostatin A (TSA) in lung cancer cell lines led to the activation of E-cad.

To date, eleven mammalian HDACs have been identified and grouped into 3 classes (Class I-III). HDAC inhibitors are an emerging class of therapeutic agents that promote

differentiation and apoptosis in hematologic and solid malignancies through chromatin remodeling and gene expression regulation. Several HDAC inhibitors were identified including benzamides (MS-275), short-chain fatty acids (*i.e.*, Sodium phenylbutyrate); hydroxamic acids (*i.e.*, suberoylanilide hydroxamic acid and trichostatin A); cyclic  
5 tetrapeptides containing a 2-amino-8-oxo-9, 10-epoxy-decanoyl moiety (*i.e.*, trapoxin A) and cyclic peptides without the 2-amino-8-oxo-9, 10-epoxy-decanoyl moiety (*i.e.*, FK228). The majority of these are undergoing clinical trials. MS-275 (Schering AG) is a benzamide HDAC inhibitor undergoing Phase I investigation in hematologic and solid malignancies. MS-275 is rapidly absorbed and has a half-life of 100 hours; changes in histone acetylation  
10 have persisted for several weeks following the administration of MS-275.

It is of great interest to identify patients that would benefit from EGFR inhibitors and to identify treatments that can improve the responsiveness of cancer cells which are resistant to EGFR inhibitors, particularly for use in cancer cells that express EGFR. In particular, it would be desirable to find treatment regimens that would increase the  
15 sensitivity of a cancer cell line that expresses EGFR to EGFR inhibitors.

#### Summary of the Invention

One embodiment of the present invention relates to a method to treat a patient with cancer. The method includes the step of administering to the patient a combination of at  
20 least one histone deacetylase (HDAC) inhibitor and at least one epidermal growth factor receptor (EGFR) inhibitor. In one aspect, the combination is administered sequentially. For example, in this aspect, at least a substantial portion of the HDAC inhibitor can be administered before a substantial portion of the EGFR inhibitor is administered. In one aspect, the HDAC inhibitor is MS-275 and the EGFR inhibitor is gefitinib. In this aspect,  
25 the dosing regime can include administration of MS-275 at 2 mg/m<sup>2</sup> orally weekly for 4 weeks followed by administration of gefitinib at 250 mg orally per day for 4 weeks. In another aspect, the combination is administered over substantially the same time period. For example, in this aspect, the dosing regime can include administration of MS-275 at 2 mg/m<sup>2</sup> orally weekly for 4 weeks coadministered with gefitinib at 250 mg orally per day for  
30 4 weeks.

Another embodiment of the present invention relates to a method to treat a patient with an epidermal growth factor receptor (EGFR) inhibitor-resistant cancer by sensitizing the cancer cells to EGFR inhibitors. The method includes administering to the patient a

combination of at least one histone deacetylase (HDAC) inhibitor and at least one EGFR inhibitor. In one aspect of this embodiment, the method additionally comprises the step of evaluating the cancer to predict resistance to an EGFR inhibitor prior to administration of the therapeutic composition. For example, the step of evaluating the cancer can include: (a) detecting in a sample of tumor cells from a patient a level of a biomarker selected from: (i) a level of amplification of the epidermal growth factor receptor (EGFR) gene; (ii) a level of polysomy of the EGFR gene; (iii) a level of amplification of the human tyrosine kinase receptor-type receptor (HER2) gene; and (iv) a level of polysomy of the HER2 gene; (b) comparing the level of the biomarker in the tumor cell sample to a control level of the biomarker selected from: (i) a control level of the biomarker that has been correlated with sensitivity to the EGFR inhibitor; and (ii) a control level of the biomarker that has been correlated with resistance to the EGFR inhibitor; and (c) selecting the patient as being predicted to not benefit from therapeutic administration of the EGFR inhibitor, or being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of the biomarker in the patient's tumor cells is statistically less than the control level of the biomarker that has been correlated with sensitivity to the EGFR inhibitor, or if the level of the biomarker in the patient's tumor cells is statistically similar to or less than the level of the biomarker that has been correlated with resistance to the EGFR inhibitor.

In another aspect of this embodiment, the method additionally comprises the steps of: (a) detecting a level of expression of epidermal growth factor receptor (EGFR) protein in the tumor cell sample; (b) comparing the level of EGFR protein expression in the tumor cell sample to a control level of EGFR protein expression selected from: (i) a control level that has been correlated with sensitivity to the EGFR inhibitor; and (ii) a control level that has been correlated with resistance to the EGFR inhibitor; and (c) selecting the patient as being predicted to not benefit from therapeutic administration of the EGFR inhibitor, or being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of EGFR protein expression in the patient's tumor cells is statistically less than the control level of EGFR protein expression that has been correlated with sensitivity to the EGFR inhibitor, or if the level of EGFR protein expression in the patient's tumor cells is statistically similar to or less than the level of EGFR protein expression that has been correlated with resistance to the EGFR inhibitor.

In a further aspect of this embodiment, the method includes the additional steps of: (d) detecting in the sample of tumor cells a level of expression of the E-cadherin protein; (e)

comparing the level of E-cadherin expression in the tumor cell sample to a control level of E-cadherin expression selected from: (i) a control level that has been correlated with sensitivity to an EGFR inhibitor; and (ii) a control level that has been correlated with resistance to an EGFR inhibitor; and (f) selecting the patient as being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of E-cadherin expression in the patient's tumor cells is statistically reduced compared to the control level of E-cadherin expression that has been correlated with sensitivity to an EGFR inhibitor, or if the level of E-cadherin expression in the patient's tumor cells is statistically similar than the level of E-cadherin expression that has been correlated with resistance to an EGFR inhibitor.

In another further aspect of this embodiment, the method includes the additional steps of: (d) detecting in the sample of tumor cells a level of expression of at least one component of TF8; (e) comparing the level of expression of at least one component of TF8 in the tumor cell sample to a control level of expression of at least one component of TF8 selected from: (i) a control level that has been correlated with sensitivity to an EGFR inhibitor; and (ii) a control level that has been correlated with resistance to an EGFR inhibitor; and (f) selecting the patient as being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of expression of at least one component of TF8 in the patient's tumor cells is statistically increased compared to the control level of expression of at least one component of TF8 that has been correlated with sensitivity to an EGFR inhibitor, or if the level of expression of at least one component of TF8 in the patient's tumor cells is statistically similar than the level of expression of at least one component of TF8 that has been correlated with resistance to an EGFR inhibitor.

Yet another embodiment of the invention relates to a method to treat a patient with a cancer that is resistant to at least one epidermal growth factor receptor (EGFR) inhibitor, comprising administering to the patient a combination of at least one histone deacetylase (HDAC) inhibitor and at least one epidermal growth factor receptor (EGFR) inhibitor, wherein the cancer is an epithelial malignancy.

In any of the embodiments of the present invention, the HDAC inhibitor can include, but is not limited to, a hydroxamic acid, a carboxylic acid, a benzamide, an epoxide, a short-chain fatty acid, a cyclic tetrapeptide containing a 2-amino-8-oxo-9, 10-epoxy-decanoyl moiety, and a cyclic peptide without the 2-amino-8-oxo-9, 10-epoxy-decanoyl moiety. A hydroxamic acid can include, but is not limited to, suberoylanilidine hydroxamic acid, TSA,

and SAHA. A carboxylic acid can include, but is not limited to, butanoic acid, valproic acid, and 4-phenylbutanoic acid. A benzamide can include, but is not limited to, N-acetyldinaline and MS-275. An epoxide can include, but is not limited to, trapoxin, depeudecin, and depsipeptide FK 228. In a preferred embodiment, the HDAC inhibitor is MS-275. In one aspect, MS-275 is administered in a dosing regime comprising administering MS-275 at 2 mg/m<sup>2</sup> orally weekly for 4 weeks or at 4 mg/m<sup>2</sup> orally biweekly for 4 weeks.

In any of the embodiments of the present invention, the EGFR inhibitor can include, but is not limited to, gefitinib, erlotinib, an agonist of gefitinib and an agonist of erlotinib. In a preferred embodiment, the EGFR inhibitor is gefitinib or erlotinib. Gefitinib can be administered, for example, in a dosing regime comprising administration of 250 mg PO per day. Erlotinib can be administered, for example, in a dosing regime comprising administration of 150 mg PO per day.

In any of the above-described embodiments of the invention, the cancer can include, but is not limited to, an epithelial malignancy, a lung cancer (*e.g.*, a non-small cell lung cancer). In one aspect, the cancer is resistant to EGFR inhibitors. For example, in one aspect, the cancer comprises cancerous cells having low or no gain in copy number of the EGFR gene or low or no gain in copy number of the HER2 gene, or a combination thereof, as compared to cancerous cells that are sensitive to EGFR inhibitors. In one aspect, the cancer comprises cancerous cells having reduced expression of EGFR protein as compared to cancerous cells that are sensitive to EGFR inhibitors. In one aspect, the cancer comprises cancerous cells having a reduced level of E-cadherin gene expression as compared to cancerous cells that are sensitive to EGFR inhibitors. In one aspect, the cancer comprises cancerous cells having an enhanced level of at least one component of TF8 expression as compared to cancerous cells that are sensitive to EGFR inhibitors. Such a component can include ZEB1.

Another embodiment of the present invention relates to a method to select a cancer patient who is predicted to benefit from therapeutic administration of a combination of at least one histone deacetylase (HDAC) inhibitor and at least one epidermal growth factor receptor (EGFR) inhibitor. The method includes the steps of: (a) detecting in the sample of tumor cells a level of expression of the E-cadherin protein; (b) comparing the level of E-cadherin expression in the tumor cell sample to a control level of E-cadherin expression selected from: (i) a control level that has been correlated with sensitivity to an EGFR



inhibitor; and (ii) a control level that has been correlated with resistance to an EGFR inhibitor; and (c) selecting the patient as being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of E-cadherin expression in the patient's tumor cells is statistically reduced compared to the control level of E-cadherin expression that has been correlated with sensitivity to an EGFR inhibitor, or if the level of E-cadherin expression in the patient's tumor cells is statistically similar than the level of E-cadherin expression that has been correlated with resistance to an EGFR inhibitor.

Another embodiment of the present invention relates to a method to select a cancer patient who is predicted to benefit from therapeutic administration of a combination of at least one histone deacetylase (HDAC) inhibitor and at least one epidermal growth factor receptor (EGFR) inhibitor. The method includes the steps of: (a) detecting in the sample of tumor cells a level of amplification of zinc finger transcription factor genes; (b) comparing the level of amplification of zinc finger transcription factor genes in the tumor cell sample to a control level of amplification of zinc finger transcription factor genes selected from: (i) a control level that has been correlated with sensitivity to an EGFR inhibitor; and (ii) a control level that has been correlated with resistance to an EGFR inhibitor; and (c) selecting the patient as being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of amplification of zinc finger transcription factor genes in the patient's tumor cells is statistically greater compared to the control level of amplification of zinc finger transcription factor genes that has been correlated with sensitivity to EGFR inhibitors, or if the level of amplification of zinc finger transcription factor genes in the patient's tumor cells is statistically similar than the level of amplification of zinc finger transcription factor genes that has been correlated with resistance to EGFR inhibitors.

#### Brief Description of the Figures of the Invention

Fig. 1A is schematic drawing showing the general structure of HDAC inhibitors.

Fig. 1B shows examples of HDAC inhibitory chemicals. TSA(1) and SAHA(2) are hydroxamic acids; butanoic acid(3), valproic acid(4) and 4-phenylbutanoic acid(5) are carboxylic acids; MS-275(6) and N-acetyldinaline(7) are benzamides; depeudecin(8) and trapoxine A(9) are epoxides; also shown are apicidin(10) and depsipeptide FK228(11).

Fig. 2 is a graph showing the effect of treatment with gefitinib alone or a combination of gefitinib and MS-275 on H175 cells.

### Detailed Description of the Invention

The present invention generally relates to a method to treat a patient with cancer, and particularly a cancer that expresses epidermal growth factor receptor (EGFR) and is resistant to EGFR inhibitors, such as gefitinib. The present inventors have discovered that

5 EGFR resistant cancers such as EGFR resistant non-small cell lung cancer (NSCL) have greater responsiveness rates to EGFR therapy when pre-treated or co-treated with a histone deacetylase inhibitor. The method generally includes administering to such patient a combination type therapy comprising a histone deacetylase inhibitor and an EGFR inhibitor. In one embodiment, the histone deacetylase inhibitor and the EGFR inhibitor are

10 administered in sequential order. The method also includes evaluating a patient's cancer for sensitivity or resistance to an EGFR inhibitor by detecting in a sample of tumor cells from a patient for a level of amplification of the epidermal growth factor receptor (EGFR) gene (i.e., the gene encoding EGFR) and/or a level of polysomy of the epidermal growth factor receptor (EGFR) gene or lack thereof as compared to an EGFR inhibitor-sensitive or

15 resistant tumor cell control. The methods of the present invention can include additionally or alternatively detecting in a sample of tumor cells a level of enhanced expression of the E-cadherin protein or transcript, or a level of decreased expression of the ZEB-1 protein or transcript as compared to an EGFR inhibitor-sensitive or resistant tumor cell control.

The present inventors have discovered molecules that predict a response (sensitivity)

20 or resistance to EGFR inhibitors for cancer treatment. NSCLC cell lines were used as a model to identify potential molecules and to develop strategies that enhance the effect of EGFR inhibitors in NSCLC. Using Western blot analysis and real time RT-PCR, the inventors found expression of E-cadherin in five UCCC cell lines sensitive to EGFR inhibitors. The expression of E-cadherin is inhibited by zinc finger inhibitory proteins.

25 Using real-time RT-PCR, the expression of the zinc-finger transcription factor was found to be elevated in gefitinib-resistant cell lines and its expression was lacking in gefitinib-sensitive ones. Overexpression of E-cadherin in NSCLC cell lines resistant to gefitinib increased their sensitivity. Inducing the expression of E-cadherin either alone or by the HDAC inhibitor, MS-275, in the most resistant cell lines led to an apoptotic effect similar to

30 what is found in cell lines harboring the EGFR mutation. The inventors found that the expression of E-cadherin, and ZEB1 predicts response to EGFR tyrosine kinase inhibitors, and pretreatment with HDAC inhibitors reverses resistance to EGFR inhibitors. In short, the present inventors have evaluated the expression of E-cad and its regulating molecules in

NSCLC cell lines, and have found that E-cad expression is lacking or reduced in cell lines resistant to the EGFR inhibitor gefitinib and activated in sensitive cell lines..

The inventors have also discovered that cell lines resistant to EGFR inhibitors have high expression of TF8. In particular, the present inventors have shown the reversal of sensitivity of NSCLC cell lines to gefitinib by restoring E-cad expression and by priming cells with the HDAC inhibitor, MS-275, and by treating cells with combination therapy using EGFR inhibitors and HDAC inhibitors. The present inventors propose herein the first known strategy directed to overcoming resistance to EGFR inhibitors in patients with lung cancer and other types of solid tumors.

The present invention also includes the administration of the combination therapy with EGFR inhibitors and HDAC inhibitors to patients who are predicted to particularly benefit from such treatment, including patients with a history of non-responsiveness to EGFR inhibitors, and patients who are predicted to be less responsive or non-responsive to treatment with EGFR inhibitors (*e.g.*, based on a test to determine resistance or sensitivity). A particularly preferred method for selecting patients who are predicted to be responsive or non-responsive to treatment with EGFR inhibitors is described in PCT Publication No. WO 2005/117553, which is incorporated by reference herein in its entirety. In the present invention, the present inventors propose that these criteria can be used to identify patients that are predicted to benefit from the combination of EGFR inhibitor and HDAC inhibitor. In particular, patients that are predicted to be resistant to (non-responsive to) EGFR inhibitor treatment, as identified using the methods described in PCT Publication No. WO 2005/117553 may particularly benefit from the method of treatment of the present invention. In addition, even patients who are predicted to be likely to respond to (be sensitive to) EGFR inhibitor treatment can also be treated using the method of the present invention.

Specifically, as described in PCT Publication No. WO 2005/117553, the use of combinations of the following markers identify patients that will be sensitive or resistant to EGFR inhibitors: (1) detection of the level of amplification of the epidermal growth factor receptor (EGFR) gene (*i.e.*, the gene encoding EGFR); (2) detection of a level of polysomy of the epidermal growth factor receptor (EGFR) gene; (3) detection of a level of gene amplification of the HER2 gene; (4) detection of the level of polysomy of the HER2 gene; (5) detection of mutations in the EGFR gene; (6) detection of EGFR protein expression; and (7) detection of phosphorylated Akt expression. For example, this publication discloses that

patients with tumor cells displaying EGFR gene amplification and/or high polysomy with respect to the EGFR gene (also generally referred to herein as an increase in EGFR gene copy number or a gain in EGFR copy number), and/or HER2 gene amplification and/or high polysomy (also generally referred to herein as an increase in HER2 gene copy number or a gain in HER2 copy number) with respect to the HER2 gene, are predicted to be especially responsive to treatment with EGFR inhibitors, and are therefore the best candidates for the use of this line of therapy. In contrast, patients having tumors with little or no gain in copy number of the EGFR and/or HER2 genes are predicted to have a poor outcome to treatment with EGFR inhibitors. These patients may be particularly good candidates for therapy using the present invention. This publication also discloses that for patients that are EGFR negative (i.e., not predicted to respond to EGFR inhibitors based on EGFR results alone), if such patients' tumors have HER2 gene amplification and/or polysomy (e.g., high trisomy or low or high polysomy) of the HER2 gene, the patient outcome is better as compared to patients without HER2 gene amplification. Furthermore, for patients that are predicted to respond to EGFR inhibitors based on EGFR results alone, HER2 gene amplification and/or high polysomy in these patients' tumors is predictive of even greater sensitivity to the EGFR inhibitor treatment than in the absence of the HER2 gene amplification. This publication also discloses that EGFR protein expression can be used to predict patient outcome with EGFR inhibitor treatment, using assessment criteria that accounts for both expression intensity and the fraction of expression-positive cells in a sample, wherein patients having tumor cells in the upper 50% of the scoring protocol (i.e., denoted positive/high EGFR expressors) had much better outcomes (e.g., better response times, slower progression rates and longer survival times) when treated with EGFR inhibitors than those in the lower expressing groups. Furthermore, PCT Publication No. WO 2005/117553 demonstrated that the combination of detection of EGFR protein expression with HER2 or EGFR gene amplification or polysomy is significantly more predictive of patient outcome to EGFR inhibitor treatment than the detection of one or no markers. Another group of cancer patients with low/no gain of EGFR gene (e.g., "FISH-negative") and low/no expression of EGFR protein (e.g., "IHC-negative"), which constitute about 30% of the total NSCLC population, seem not to have any clinical benefit (no/very low response rate, short time to progression and short survival time) from EGFR inhibitors. These patients may also be good candidates for treatment using the combination therapy of the present invention. Finally, two other biomarkers, namely mutated EGFR genes or phosphorylated Akt

expression, can be combined with any of biomarkers and protocols discussed above to improve the ability to detect patients predicted to respond to EGFR inhibitor treatment. For example, PCT Publication No. WO 2005/117553 demonstrates that the combination of detection of mutations in the EGFR gene with EGFR protein expression, EGFR gene  
5 amplification and/or polysomy, and/or HER2 gene amplification and/or polysomy, can be used to select patients who will have clinical benefit from EGFR inhibitor therapy. The combination of the detection of phosphorylated Akt (i.e., activated Akt) with detection of EGFR protein expression and/or detection of EGFR gene amplification and/or polysomy can be used to select patients who will have clinical benefit from EGFR inhibitor therapy.  
10 Accordingly, patients selected by any of these criteria to be poor or non-responders to EGFR inhibitor therapy are particularly good candidates for treatment using the method of the invention.

Additionally or alternatively, patients with tumor cells having reduced or absent E-cad expression also show the phenotype of an EGFR inhibitor-resistant cancer and are  
15 candidates for the combination therapy as disclosed in the present invention. Additionally or alternatively, patients with tumor cells having activated or enhanced TF-8 expression also show the phenotype of an EGFR inhibitor-resistant cancer and are candidates for the combination therapy as disclosed in the present invention.

However, the present invention is not limited to any of these candidate patients  
20 discussed above, since any cancer patient can benefit from the use of the combination therapy disclosed in the present invention.

Various definitions and aspects of the invention will be described below, but the invention is not limited to any specific embodiments that may be used for illustrative or exemplary purposes.

25 In a first embodiment of the present invention, the present invention includes a method to treat a patient with cancer, comprising administering to the patient a combination of an effective amount of a therapeutic composition comprising at least one histone deacetylase inhibitor and an effective amount of a therapeutic composition comprising at least one EGFR inhibitor. The method also includes a method to treat a patient with a  
30 cancer that is resistant to at least one EGFR inhibitor comprising administering to the patient a combination of an effective amount of a therapeutic composition comprising at least one histone deacetylase inhibitor and an effective amount of a therapeutic composition comprising at least one EGFR inhibitor, wherein said cancer is an epithelial malignancy.

The combination may be administered either sequentially or concurrently. Methods of dosing, dosing regimes, and amounts of an EGFR inhibitor and an HDAC inhibitor to administer which are effective to treat cancer are known in the art, and routine optimization may be performed by one skilled in the art to determine preferred dosing methods, regimes, and amounts of each compound to use. Such combination therapy may involve the administration of the HDAC inhibitor before, during, and/or after the administration of the EGFR inhibitor. The administration of the EGFR inhibitor may be separated in time from the administration of HDAC inhibitor by up to several weeks, and may precede it or follow it, but more commonly the administration of the EGFR inhibitor will accompany the administration of the HDAC inhibitor within up to 48 hours, and most commonly within less than 24 hours, including any increment of 30 minutes from 0 to 24 hours and higher (e.g., 30 minutes, 1 hour, 90 minutes, 2 hours, etc.).

In a preferred embodiment, at least a substantial portion of the therapeutic composition comprising at least one histone deacetylase inhibitor is administered before a substantial portion of the therapeutic composition comprising at least one EGFR inhibitor is administered. A substantial portion includes an amount of histone deacetylase inhibitor that is greater than 50% of the total dose to be delivered, and even more preferably includes greater than about 60% of the total dose to be delivered, preferably greater than about 70% of the total dose to be delivered, preferably greater than about 80% of the total dose to be delivered, preferably greater than about 90% of the total dose to be delivered, and most preferably about 100% of the total dose to be delivered. A particularly preferred dosing regime comprises administration of about 100% of the therapeutic composition comprising at least one histone deacetylase inhibitor over a preferred amount of time, followed by administration of about 100% of the therapeutic composition comprising at least one EGFR inhibitor over a preferred amount of time.

Another preferred embodiment includes administering said combination over substantially the same time period, *i.e.*, wherein at least a substantial portion of the therapeutic composition comprising at least one histone deacetylase inhibitor is administered together with a substantial portion of the therapeutic composition comprising at least one EGFR inhibitor. A substantial portion includes an amount of histone deacetylase inhibitor that is greater than 50% of the total dose to be delivered, and even more preferably includes greater than about 60% of the total dose to be delivered, preferably greater than about 70% of the total dose to be delivered, preferably greater than

about 80% of the total dose to be delivered, preferably greater than about 90% of the total dose to be delivered, and most preferably about 100% of the total dose to be delivered.

A "therapeutically effective amount" means that amount which, when administered to a mammal, especially a human, for treating a cancer, is sufficient to effect treatment for the cancer. "Treating" or "treatment" of a cancer in a mammal includes one or more of: inhibiting growth of the cancer (e.g., arresting its development), preventing spread of the cancer (e.g., preventing metastases), relieving the cancer (e.g., causing regression of the cancer), preventing recurrence of the cancer, and palliating symptoms of the cancer. As such, a therapeutic benefit or treatment is not necessarily a cure for a particular disease or condition, but rather, preferably encompasses a result which most typically includes alleviation of the disease or condition, elimination of the disease or condition, reduction of a symptom associated with the disease or condition, prevention or alleviation of a secondary disease or condition resulting from the occurrence of a primary disease or condition (e.g., metastatic tumor growth resulting from a primary cancer), and/or prevention of the disease or condition. A beneficial effect can easily be assessed by one of ordinary skill in the art and/or by a trained clinician who is treating the patient. The term, "disease" refers to any deviation from the normal health of a mammal and includes a state when disease symptoms are present, as well as conditions in which a deviation (e.g., infection, gene mutation, genetic defect, etc.) has occurred, but symptoms are not yet manifested. According to the present invention, the methods disclosed herein are suitable for use in a patient that is a member of the Vertebrate class, Mammalia, including, without limitation, primates, livestock and domestic pets (e.g., a companion animal). Most typically, a patient will be a human patient.

The EGFR inhibitor and/or the HDAC inhibitor may be administered by any route suitable to the subject being treated and the nature of the subject's condition. Routes of administration include, but are not limited to, administration by injection, including intravenous, intraperitoneal, intramuscular, and subcutaneous injection, by transmucosal or transdermal delivery, through topical applications, nasal spray, suppository and the like or may preferably be administered orally. Formulations may optionally be liposomal formulations, emulsions, formulations designed to administer the drug across mucosal membranes or transdermal formulations. Suitable formulations for each of these methods of administration may be found, for example, in Remington: The Science and Practice of Pharm, 20th ed., A. Gennaro, ed., Lippincott Williams & Wilkins, Philadelphia, Pa., U.S.A.

Typical formulations will be either oral or solutions for intravenous infusion. Typical dosage forms will be tablets (for oral administration), solutions for intravenous infusion, and lyophilized powders for reconstitution as solutions for intravenous infusion, although any suitable dosage form is encompassed by the present invention. Kits may contain an HDAC inhibitor and the EGFR inhibitor, also in dosage form, for example packaged together in a common outer packaging.

A therapeutic composition of the present invention may include, in addition to the HDAC inhibitors and/or EGFR inhibitors of the present invention, conventional pharmaceutical excipients, and other conventional, pharmaceutically inactive agents. Additionally, the compositions may include active agents in addition to the HDAC inhibitors and/or EGFR inhibitors of the present invention. These additional active agents may include one or more other pharmaceutically active agents. The compositions may be in gaseous, liquid, semi-liquid or solid form, formulated in a manner suitable for the route of administration to be used. For oral administration, capsules and tablets are typically used. For parenteral administration, reconstitution of a lyophilized powder, prepared as described herein, is typically used. The compositions may further comprise: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polyvinylpyrrolidone, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents. Actual methods of preparing such dosage forms are known in the art, or will be apparent, to those skilled in this art. The composition or formulation to be administered will, in any event, contain a sufficient quantity of a HDAC inhibitor and/or EGFR inhibitor of the present invention to reduce such activity *in vivo*, thereby treating the disease state of the subject.



Dosage forms or compositions may optionally comprise one or more of an HDAC inhibitor and/or EGFR inhibitor according to the present invention in the range of 0.005% to 100% (weight/weight) with the balance comprising additional substances such as those described herein. For oral administration, a pharmaceutically acceptable composition may optionally comprise any one or more commonly employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum. Such compositions include solutions, suspensions, tablets, capsules, powders, dry powders for inhalers and sustained release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparing these formulations are known to those skilled in the art. The compositions may optionally contain 0.01%-100% (weight/weight) of one or more of an HDAC inhibitor and/or EGFR inhibitor of the present invention; optionally 0.1-95%, and optionally 1-95%.

Salts, preferably sodium salts, of an HDAC inhibitor and/or EGFR inhibitor of the present invention may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings. The formulations may further include other active compounds to obtain desired combinations of properties. Oral pharmaceutical dosage forms may be as a solid, gel or liquid. Examples of solid dosage forms include, but are not limited to tablets, capsules, granules, and bulk powders. More specific examples of oral tablets include compressed, chewable lozenges and tablets that may be enteric-coated, sugar-coated or film-coated. Examples of capsules include hard or soft gelatin capsules. Granules and powders may be provided in non-effervescent or effervescent forms. Each may be combined with other ingredients known to those skilled in the art. In certain embodiments, HDAC inhibitors according to the present invention are provided as solid dosage forms, preferably capsules or tablets. The tablets, pills, capsules, troches and the like may optionally contain one or more of the following ingredients, or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a glidant; a sweetening agent; and a flavoring agent. Examples of binders that may be used include, but are not limited to, microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, sucrose and starch paste. Examples of lubricants that may be used include, but are not limited to, talc, starch, magnesium or calcium stearate,

lycopodium and stearic acid. Examples of diluents that may be used include, but are not limited to, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate. Examples of glidants that may be used include, but are not limited to, colloidal silicon dioxide. Examples of disintegrating agents that may be used include, but are not limited to, crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose. Examples of coloring agents that may be used include, but are not limited to, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate. Examples of sweetening agents that may be used include, but are not limited to, sucrose, lactose, mannitol and artificial sweetening agents such as sodium cyclamate and saccharin, and any number of spray-dried flavors. Examples of flavoring agents that may be used include, but are not limited to, natural flavors extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate. Examples of wetting agents that may be used include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether. Examples of anti-emetic coatings that may be used include, but are not limited to, fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates. Examples of film coatings that may be used include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate. If oral administration is desired, the salt of the compound may optionally be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric-coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in combination with an antacid or other such ingredient. Compounds according to the present invention may also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like. A syrup may optionally comprise, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

An HDAC inhibitor-containing therapeutic composition compatible with the methods of the present invention includes a composition comprising an HDAC inhibitor such as, for example, hydroxamic acids such as suberoylanilidine hydroxamic acid, TSA, and SAHA (NVP-LAQ-824, PXD-1-1); carboxylic acids such as butanoic, valproic, and 4-

phenylbutanoic acids; benzamides such as N-acetyldinaline and MS-275; epoxides such as trapoxins, depeudecin, depsipeptide FK 228; short-chain fatty acids; a cyclic tetrapeptide containing a 2-amino-8-oxo-9, 10-epoxy-decanoyl moiety, and a cyclic peptide without the 2-amino-8-oxo-9, 10-epoxy-decanoyl moiety. See Fig. 1. A particularly preferred HDAC inhibitor is MS-275.

Preferred amounts of HDAC inhibitor to administer may be chosen by one of skill in the art, and include amounts known in the art to be efficacious for treating cancers. Examples of suitable methods to treat cancer with HDAC inhibitors and suitable amounts of HDAC inhibitors to use are known in the art, such as, for example, in U.S. Patent Publication 20040132825, U.S. Serial No. 10/692,523, Bacopoulos et al., entitled METHODS OF TREATING CANCER WITH HDAC INHIBITORS, filed October 24, 2003, which is incorporated herein by reference in its entirety. Suitable dosing for an HDAC inhibitor includes dosing already established for that HDAC inhibitor, as described in such documents as those listed herein and as known in the art. A preferred amount to administer for MS-275, for example, includes a minimum of about 0.01 milligram per meter squared ( $\text{mg}/\text{m}^2$ ) and a maximum of about 1,000  $\text{mg}/\text{m}^2$ , and can include ranges between: about 0.1  $\text{mg}/\text{m}^2$  and about 100  $\text{mg}/\text{m}^2$ , about 0.2  $\text{mg}/\text{m}^2$  and about 90  $\text{mg}/\text{m}^2$ , about 0.3  $\text{mg}/\text{m}^2$  and about 70  $\text{mg}/\text{m}^2$ , about 0.4  $\text{mg}/\text{m}^2$  and about 50  $\text{mg}/\text{m}^2$ , about 0.5  $\text{mg}/\text{m}^2$  and about 30  $\text{mg}/\text{m}^2$ , about 0.6  $\text{mg}/\text{m}^2$  and about 20  $\text{mg}/\text{m}^2$ , about 0.7  $\text{mg}/\text{m}^2$  and about 15  $\text{mg}/\text{m}^2$ , about 0.8  $\text{mg}/\text{m}^2$  and about 10  $\text{mg}/\text{m}^2$ , about 0.9  $\text{mg}/\text{m}^2$  and about 5  $\text{mg}/\text{m}^2$ . Other preferred amounts to administer include about 0.1  $\text{mg}/\text{m}^2$ , about 0.5  $\text{mg}/\text{m}^2$ , about 1  $\text{mg}/\text{m}^2$ , about 1.5  $\text{mg}/\text{m}^2$ , about 2  $\text{mg}/\text{m}^2$ , about 2.5  $\text{mg}/\text{m}^2$ , about 3  $\text{mg}/\text{m}^2$ , about 3.5  $\text{mg}/\text{m}^2$ , about 4  $\text{mg}/\text{m}^2$ , about 4.5  $\text{mg}/\text{m}^2$ , about 5  $\text{mg}/\text{m}^2$ , about 5.5  $\text{mg}/\text{m}^2$ , about 6  $\text{mg}/\text{m}^2$ , about 6.5  $\text{mg}/\text{m}^2$ , about 7  $\text{mg}/\text{m}^2$ , and about 7.5  $\text{mg}/\text{m}^2$ . The dosing can occur over any time period, for example daily, every 2-6 days, biweekly, monthly, or in one aspect, weekly. In preferred embodiments, one may administer HDAC inhibitory compounds of the present invention orally, although one can also administer by intravenous and intramuscular injection. In one embodiment, an HDAC inhibitor such as MS-275 is administered at 2  $\text{mg}/\text{m}^2$  orally weekly for 3 out of 4 weeks or 4  $\text{mg}/\text{m}^2$  orally biweekly.

An EGFR inhibitor-containing therapeutic composition compatible with the methods of the present invention includes a composition comprising an EGFR inhibitor. Currently there are two main classes of EGFR inhibitors: anti-EGFR family tyrosine kinase inhibitors (small molecules) and anti-EGFR monoclonal antibodies. Examples of small

molecules include EGFR-specific and reversible inhibitors such as, for example, gefitinib (IRESSA<sup>®</sup>, ZD1839), erlotinib (TARCEVA<sup>®</sup>, OSI-774, CP-358), or PKI-166; EGFR-specific and irreversible inhibitors, such as EKI-569; a PAN-HER (human EGF receptor family) reversible inhibitor, such as GW2016 (targets both EGFR and Her2/neu); and a

5 PAN-HER irreversible inhibitor, such as CI-1033 (4-anilinoquinazoline). Examples of monoclonal antibodies include C225 (CETUXIMAB), ABX-EGF (human) (Abgenics, San Francisco, CA), EMD-72000 (humanized), h-R3 (humanized), and MDX-447 (bi-specific, EGFR-CK64). Therapeutic compositions also include a drug having substantially the same biological activity as gefitinib and erlotinib. A particularly preferred EGFR inhibitor is

10 gefitinib and/or erlotinib. Preferred amounts of EGFR inhibitor to administer may be chosen by one of skill in the art, and include amounts known in the art to be efficacious for treating other cancers. Suitable dosing for an EGFR inhibitor will be the dosing already established for that EGFR inhibitor, as described in such documents as those listed below and known in the art. Examples of suitable methods to treat cancer with EGFR inhibitors

15 and suitable amounts of EGFR inhibitors to use are known in the art, such as, for example, in U.S. Patent Publication 20030114504, U.S. Serial No. 10/228,544, Webster et al., entitled COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER, filed August 27, 2002, which is incorporated herein by reference in its entirety. A preferred amount to administer or treat with includes a minimum of about 5 mg and a maximum of

20 about 20,000 mg, and can include ranges between: about 20 mg and about 15,000 mg, about 40 mg and about 10,000 mg, about 80 mg and about 5000 mg, about 120 mg and about 2000 mg, about 180 mg and about 1500 mg, about 200 mg and about 1000 mg, about 250 mg and about 800 mg, about 300 mg and about 700 mg, about 400 mg and about 600 mg. Other preferred amounts include about 10 mg, about 50 mg, about 100 mg, about 150

25 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1200 mg, about 1400 mg, about 1600 mg, about 1800 mg, about 2000 mg, about 2200 mg, about 2400 mg, about 2600 mg, about 2800 mg, about 3000 mg, about 3500 mg, about

30 4000 mg, about 4500 mg, about 5000 mg, about 5500 mg, about 6000 mg, about 6500 mg, about 7000 mg, about 8000 mg, about 10,000 mg, about 12,000 mg, and about 15,000 mg. The dosing will be over any time period, preferably monthly, more preferably weekly, and even more preferably daily.

In one embodiment, one may administer EGFR inhibitory compounds of the present invention orally, although one can also administer them by intravenous and intramuscular injection. In one embodiment, an EGFR inhibitor is gefitinib and is administered orally in a bolus of about 2,000 mg once per week. In another embodiment, the EGFR inhibitor is gefitinib and is administered daily at about 250 mg per day. In another embodiment, the inhibitor is erlotinib and is administered orally at about 150 mg per day.

Periods of time in which to administer any HDAC inhibitors and/or EGFR inhibitors are either known in the art and/or may be determined by one of skill in the art, and include for about a day, for about 2 days, for about 3 days, for about 4 days, for about 5 days, for about 6 days, for about a week, for about a week and a half, for about 2 weeks, for about 2 and a half weeks, for about 3 weeks, for about three and a half weeks, for about 4 weeks, for about 5 weeks, for about 6 weeks, for about 8 weeks, for about 10 weeks, for about 15 weeks, for about 20 weeks, for about 25 weeks, for about 30 weeks, for about 40 weeks, and for about 52 weeks. The HDAC inhibitors and/or EGFR inhibitors may be optionally administered over successive periods of time with one or more rest periods (i.e., no administration of HDAC inhibitors and/or EGFR inhibitors). Rest periods again are either known in the art and/or may be determined by one of skill in the art, and include for about a day, for about 2 days, for about 3 days, for about 4 days, for about 5 days, for about 6 days, for about a week, for about a week and a half, for about 2 weeks, for about 2 and a half weeks, for about 3 weeks, for about three and a half weeks, for about 4 weeks, for about 5 weeks, for about 6 weeks, for about 8 weeks, for about 10 weeks, for about 15 weeks, for about 20 weeks, for about 25 weeks, for about 30 weeks, for about 40 weeks, and for about 52 weeks.

Preferred cancers to treat with the methods of the present invention include cancers that are epithelial malignancies, and particularly any cancers (tumors) that express EGFR. A preferred cancer to treat is a cancer that is resistant to EGFR inhibitors and in one aspect, can be an epithelial malignancy that is resistant to EGFR inhibitors. In an EGFR inhibitor-resistant cancer, the cancer can include tumors (cancerous cells) with little or no gain in copy number (low/no gene amplification or polysomy). tumors that are low expressors (in the lower 50% of an appropriate scoring protocol, as in PCT Publication No. WO 2005/117553) of EGFR protein, or especially a combination of low/no gain of EGFR gene and low/no expression of EGFR protein. EGFR-resistant cancers can also include tumors that have low/no gain in EGFR and are P-Akt positive, or tumors with EGFR gene

amplification and/or polysomy, but that are P-Akt negative. EGFR-resistant cancers can also include tumors without mutations in EGFR that meet one or more of the other criteria for poor or non-responders as discussed above.

5 In another preferred EGFR-resistant cancer, the cancer preferably comprises cancerous cells having a reduced level of E-cadherin gene expression compared to cancerous cells that are sensitive to EGFR inhibitors. In yet another preferred EGFR-resistant cancer, the cancer preferably comprises cancerous cells having an enhanced level of zinc finger transcription factors expression compared to cancerous cells that are sensitive to EGFR inhibitors. A preferred zinc finger transcription factor is TF8. Another preferred  
10 type of cancer to treat is a lung cancer, and particularly preferred is a lung cancer that is derived from an epithelial cell, such as non-small cell lung cancer.

The methods of the present invention also include a method to treat a patient with an EGFR inhibitor-resistant cancer comprising the step of sensitizing the cancer cells resistant to at least one EGFR inhibitor comprising administering to the patient a  
15 combination of an effective amount of a therapeutic composition comprising at least one histone deacetylase (HDAC) inhibitor and an effective amount of a therapeutic composition comprising at least one EGFR inhibitor.

The methods of the present invention can also include an additional step comprising the step of evaluating the cancer to predict sensitivity to or for resistance to EGFR  
20 inhibitors. The method can include evaluating any of the markers described above that are predictive of poor or non-responsiveness to EGFR inhibitor therapy. For example, in one embodiment, the step of evaluating the cancer for sensitivity or resistance to an EGFR inhibitor comprises: a) detecting in a sample of tumor cells from a patient to be tested a level of amplification of the epidermal growth factor receptor (EGFR) gene and/or a level  
25 of polysomy of the epidermal growth factor receptor (EGFR) gene; b) comparing the level of EGFR gene amplification and/or polysomy in the tumor cell sample to a control level of EGFR gene amplification and/or polysomy selected from the group consisting of: i) a control level that has been correlated with sensitivity to an EGFR inhibitor; and ii) a control level that has been correlated with resistance to an EGFR inhibitor; and c) selecting the  
30 patient as being predicted to benefit from therapeutic administration of the combination, if the level of EGFR gene amplification and/or polysomy in the patient's tumor cells is decreased relative to the control level of EGFR gene amplification and/or polysomy that has been correlated with sensitivity to EGFR inhibitor, or if the level of EGFR gene

amplification and/or polysomy in the patient's tumor cells is statistically similar than the level of level of EGFR gene amplification and/or polysomy that has been correlated with resistance to an EGFR inhibitor. Other similar steps of evaluating the tumor can be performed based on the criteria discussed herein.

5 In another embodiment, the step of evaluating the cancer for sensitivity or resistance to an EGFR inhibitor may additionally or alternately comprise detecting in the sample of tumor cells a level of expression of the E-cadherin protein; comparing the level of E-cadherin expression in the tumor cell sample to a control level of E-cadherin expression being either a control level that has been correlated with sensitivity to an EGFR inhibitor  
10 or a control level that has been correlated with resistance to an EGFR inhibitor; and selecting the patient as being predicted to benefit from therapeutic administration of combination, if the level of E-cadherin expression in the patient's tumor cells is statistically reduced compared to the control level of E-cadherin expression that has been correlated with sensitivity to an EGFR inhibitor, or if the level of E-cadherin expression in the patient's  
15 tumor cells is statistically similar than the level of E-cadherin expression that has been correlated with resistance to an EGFR inhibitor.

In another embodiment, the step of evaluating the cancer for sensitivity or resistance to an EGFR inhibitor may additionally or alternately comprise detecting in the sample of tumor cells a level of expression of at least one component of TF8; comparing the level at  
20 least one component of TF8's expression in the tumor cell sample to a control level of at least one component of TF8's expression being either: a control level that has been correlated with sensitivity to an EGFR inhibitor, or a control level that has been correlated with resistance to an EGFR inhibitor; and selecting the patient as being predicted to benefit from therapeutic administration of combination, if the level of at least one component of  
25 TF8's expression in the patient's tumor cells is statistically increased compared to the control level of at least one component of TF8's expression that has been correlated with sensitivity to an EGFR inhibitor, or if the level of at least one component of TF8's expression in the patient's tumor cells is statistically similar than the level of at least one component of TF8's expression that has been correlated with resistance to an EGFR  
30 inhibitor. A preferred component of TF8 to detect is ZEB1.

Suitable methods of obtaining a patient sample are known to a person of skill in the art. A patient sample can include any bodily fluid or tissue from a patient that may contain tumor cells or proteins of tumor cells. More specifically, according to the present invention,

the term "test sample" or "patient sample" can be used generally to refer to a sample of any type which contains cells or products that have been secreted from cells to be evaluated by the present method, including but not limited to, a sample of isolated cells, a tissue sample and/or a bodily fluid sample. Most typically in the present invention, the sample is a tissue sample. According to the present invention, a sample of isolated cells is a specimen of cells, typically in suspension or separated from connective tissue which may have connected the cells within a tissue *in vivo*, which have been collected from an organ, tissue or fluid by any suitable method which results in the collection of a suitable number of cells for evaluation by the method of the present invention. The cells in the cell sample are not necessarily of the same type, although purification methods can be used to enrich for the type of cells that are preferably evaluated. Cells can be obtained, for example, by scraping of a tissue, processing of a tissue sample to release individual cells, or isolation from a bodily fluid.

A tissue sample, although similar to a sample of isolated cells, is defined herein as a section of an organ or tissue of the body which typically includes several cell types and/or cytoskeletal structure which holds the cells together. One of skill in the art will appreciate that the term "tissue sample" may be used, in some instances, interchangeably with a "cell sample", although it is preferably used to designate a more complex structure than a cell sample. A tissue sample can be obtained by a biopsy, for example, including by cutting, slicing, or a punch.

A bodily fluid sample, like the tissue sample, contains the cells to be evaluated, and is a fluid obtained by any method suitable for the particular bodily fluid to be sampled. Bodily fluids suitable for sampling include, but are not limited to, blood, mucous, seminal fluid, saliva, breast milk, bile and urine.

In general, the sample type (*i.e.*, cell, tissue or bodily fluid) is selected based on the accessibility and structure of the organ or tissue to be evaluated for tumor cell growth and/or on what type of cancer is to be evaluated. For example, if the organ/tissue to be evaluated is the breast, the sample can be a sample of epithelial cells from a biopsy (*i.e.*, a cell sample) or a breast tissue sample from a biopsy (a tissue sample). The present invention is particularly useful for evaluating patients with lung cancer and particularly, non-small cell lung carcinoma, and in this case, a typical sample is a section of a lung tumor from the patient.



The copy number of genes in tumor cells according to the invention can be measured in primary tumors, metastatic tumors, locally recurring tumors, ductal carcinomas in situ, or other tumors. The markers can be measured in solid tumors that are fresh, frozen, fixed or otherwise preserved. They can be measured in cytoplasmic or nuclear tumor  
5 extracts; or in tumor membranes including but not limited to plasma, mitochondrial, golgi or nuclear membranes; in the nuclear matrix; or in tumor cell organelles and their extracts including but not limited to ribosomes, nuclei, mitochondria, golgi.

Once a sample is obtained from the patient, the sample is evaluated for sensitivity or resistance to EGFR inhibitors as disclosed herein. In some embodiments of the present  
10 invention, a tissue, a cell or a portion thereof (e.g., a section of tissue, a component of a cell such as nucleic acids, etc.) is contacted with one or more nucleic acids. Such methods can include cell-based assays or non-cell-based assays. The tissue or cell expressing a target gene is typically contacted with a detection agent (e.g., a probe, primer, or other detectable marker), by any suitable method, such as by mixing, hybridizing, or combining in a manner  
15 that allows detection of the target gene by a suitable technique.

The patient sample is prepared by any suitable method for the detection technique utilized. In one embodiment, the patient sample can be used fresh, frozen, fixed or otherwise preserved. For example, the patient tumor cells can be prepared by immobilizing patient tissue in, for example, paraffin. The immobilized tissue can be sectioned and then  
20 contacted with a probe for detection of hybridization of the probe to a target gene.

In a preferred embodiment, detection of a gene according to the present invention is accomplished using hybridization assays. Nucleic acid hybridization simply involves contacting a probe (e.g., an oligonucleotide or larger polynucleotide) and target nucleic acid under conditions where the probe and its complementary target can form stable hybrid  
25 duplexes through complementary base pairing. As used herein, hybridization conditions refer to standard hybridization conditions under which nucleic acid molecules are used to identify similar nucleic acid molecules. Such standard conditions are disclosed, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press, 1989. Sambrook et al., *ibid.*, is incorporated by reference herein in its  
30 entirety (see specifically, pages 9.31-9.62). In addition, formulae to calculate the appropriate hybridization and wash conditions to achieve hybridization permitting varying degrees of mismatch of nucleotides are disclosed, for example, in Meinkoth et al., 1984, *Anal. Biochem.* 138, 267-284; Meinkoth et al., *ibid.*, is incorporated by reference herein in

its entirety. Nucleic acids that do not form hybrid duplexes are washed away from the hybridized nucleic acids and the hybridized nucleic acids can then be detected, typically through detection of an attached detectable label. It is generally recognized that nucleic acids are denatured by increasing the temperature or decreasing the salt concentration of the buffer containing the nucleic acids. Under low stringency conditions (e.g., low temperature and/or high salt) hybrid duplexes (e.g., DNA:DNA, RNA:RNA, or RNA:DNA) will form even where the annealed sequences are not perfectly complementary. Thus specificity of hybridization is reduced at lower stringency. Conversely, at higher stringency (e.g., higher temperature or lower salt) successful hybridization requires fewer mismatches.

High stringency hybridization and washing conditions, as referred to herein, refer to conditions which permit isolation of nucleic acid molecules having at least about 90% nucleic acid sequence identity with the nucleic acid molecule being used to probe in the hybridization reaction (i.e., conditions permitting about 10% or less mismatch of nucleotides). One of skill in the art can use the formulae in Meinkoth et al., 1984, *Anal. Biochem.* 138, 267-284 (incorporated herein by reference in its entirety) to calculate the appropriate hybridization and wash conditions to achieve these particular levels of nucleotide mismatch. Such conditions will vary, depending on whether DNA:RNA or DNA:DNA hybrids are being formed. Calculated melting temperatures for DNA:DNA hybrids are 10°C less than for DNA:RNA hybrids. In particular embodiments, stringent hybridization conditions for DNA:DNA hybrids include hybridization at an ionic strength of 6X SSC (0.9 M Na<sup>+</sup>) at a temperature of between about 20°C and about 35°C, more preferably, between about 28°C and about 40°C, and even more preferably, between about 35°C and about 45°C. In particular embodiments, stringent hybridization conditions for DNA:RNA hybrids include hybridization at an ionic strength of 6X SSC (0.9 M Na<sup>+</sup>) at a temperature of between about 30°C and about 45°C, more preferably, between about 38°C and about 50°C, and even more preferably, between about 45°C and about 55°C. These values are based on calculations of a melting temperature for molecules larger than about 100 nucleotides, 0% formamide and a G + C content of about 40%. Alternatively, T<sub>m</sub> can be calculated empirically as set forth in Sambrook et al., *supra*, pages 9.31 to 9.62.

The hybridized nucleic acids are detected by detecting one or more labels attached to the sample nucleic acids. The labels may be incorporated by any of a number of means well known to those of skill in the art. Detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical,

immunochemical, electrical, optical or chemical means. Useful labels in the present invention include fluorescent dyes (e.g., fluorescein, texas red, rhodamine, green fluorescent protein, and the like), radiolabels (e.g.,  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ ), and colorimetric labels. Means of detecting such labels are well known to those of skill in the art. Thus, for example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted light. Colorimetric labels are detected by simply visualizing the colored label. Preferably, the hybridizing nucleic acids are detected by fluorescent labels and most preferably, in the context of a FISH assay.

In accordance with the present invention, an isolated polynucleotide, or an isolated nucleic acid molecule, is a nucleic acid molecule that has been removed from its natural milieu (i.e., that has been subject to human manipulation), its natural milieu being the genome or chromosome in which the nucleic acid molecule is found in nature. As such, "isolated" does not necessarily reflect the extent to which the nucleic acid molecule has been purified, but indicates that the molecule does not include an entire genome or an entire chromosome in which the nucleic acid molecule is found in nature. Polynucleotides such as those used in a method of the present invention to detect genes (e.g., by hybridization to a gene) are typically a portion of the target gene that is suitable for use as a hybridization probe or PCR primer for the identification of a full-length gene (or portion thereof) in a given sample (e.g., a cell sample). An isolated nucleic acid molecule can include a gene or a portion of a gene (e.g., the regulatory region or promoter). An isolated nucleic acid molecule that includes a gene is not a fragment of a chromosome that includes such gene, but rather includes the coding region and regulatory regions associated with the gene, but no additional genes naturally found on the same chromosome. An isolated nucleic acid molecule can also include a specified nucleic acid sequence flanked by (i.e., at the 5' and/or the 3' end of the sequence) additional nucleic acids that do not normally flank the specified nucleic acid sequence in nature (i.e., heterologous sequences). Isolated nucleic acid molecule can include DNA, RNA (e.g., mRNA), or derivatives of either DNA or RNA (e.g., cDNA). Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a protein. Preferably, an isolated nucleic acid molecule

of the present invention is produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification, cloning) or chemical synthesis. If the polynucleotide is an oligonucleotide probe, the probe typically ranges from about 5 to about 50 or about 500 nucleotides, or from about 10 to about 40 nucleotides, or from about 15 to about 40  
5 nucleotides in length, or any range of length in between 10 and 1000 nucleotides, in whole integer increments (i.e., 10, 11, 12, 13...999, 1000).

According to the present invention, a probe is a nucleic acid molecule which typically ranges in size from about 8 nucleotides to several hundred nucleotides in length as discussed above. Such a molecule is typically used to identify a target nucleic acid  
10 sequence in a sample by hybridizing to such target nucleic acid sequence under stringent hybridization conditions. Hybridization conditions have been described in detail above.

PCR primers are also nucleic acid sequences, although PCR primers are typically oligonucleotides of fairly short length which are used in polymerase chain reactions. PCR primers and hybridization probes can readily be developed and produced by those of skill in  
15 the art, using sequence information from the target sequence. (See, for example, Sambrook et al., *supra* or Glick et al., *supra*).

In one embodiment, the method of the invention can also include a step of detecting whether there is a change (regulation, modification) in the level of expression of E-cad and/or a component of TF8, such as, for example ZEB1 in the cell. As used herein, the term  
20 "expression," can refer to detecting transcription of the gene and/or to detecting translation of the protein encoded by the gene. To detect expression of a gene or protein refers to the act of actively determining whether a gene or protein is expressed or not. This can include determining whether the expression is upregulated as compared to a control, downregulated as compared to a control, or unchanged as compared to a control. Expression of transcripts  
25 and/or proteins is measured by any of a variety of known methods in the art. For RNA expression, methods include but are not limited to: extraction of cellular mRNA and Northern blotting using labeled probes that hybridize to transcripts encoding all or part of one or more of the genes of this invention; amplification of mRNA expressed from one or more of the genes of this invention using gene-specific primers, polymerase chain reaction  
30 (PCR), and reverse transcriptase-polymerase chain reaction (RT-PCR), followed by quantitative detection of the product by any of a variety of means; extraction of total RNA from the cells, which is then labeled and used to probe cDNAs or oligonucleotides encoding all or part of the genes of this invention, arrayed on any of a variety of surfaces; in situ

hybridization; and detection of a reporter gene. Measurement of translation of a protein include any suitable method for detecting and/or measuring proteins from a cell or cell extract. Such methods include, but are not limited to, immunoblot (e.g., Western blot), enzyme-linked immunosorbant assay (ELISA), radioimmunoassay (RIA),  
5 immunoprecipitation, immunohistochemistry (IHC), immunofluorescence, fluorescence activated cell sorting (FACS) and immunofluorescence microscopy.

The nucleotide sequence of the human epidermal growth factor receptor (EGFR); E-cadherin; and TF8 genes are known in the art and can be found under GenBank Accession No. AY588246 (incorporated herein by reference), for example. Nucleotide probes and  
10 antibodies are also known in the art and available for use as probes to detect EGFR, E-cadherin, and TF8 (ZEB1) genes and proteins.

In the method of the invention, the level of EGFR gene amplification and/or polysomy in the tumor cell sample is compared to a control level of EGFR gene amplification and/or polysomy selected from: (i) a control level that has been correlated  
15 with sensitivity to EGFR inhibitor; and (ii) a control level that has been correlated with resistance to EGFR inhibitor. A patient is selected as being predicted to benefit from therapeutic administration of a combination therapy of the present invention, if the level of EGFR gene amplification and/or polysomy in the patient's tumor cells is statistically similar to the control level of EGFR gene amplification and/or polysomy that has been correlated  
20 with resistance to EGFR inhibitor, or if the level of EGFR gene amplification and/or polysomy in the patient's tumor cells is statistically less than or reduced from the level of EGFR gene amplification and/or polysomy that has been correlated with sensitivity to EGFR inhibitor.

In another alternate or additional method of the invention, the level of E-cadherin  
25 expression in the tumor cell sample may be compared to a control level of E-cadherin expression selected from: (i) a control level that has been correlated with sensitivity to EGFR inhibitor; and (ii) a control level that has been correlated with resistance to EGFR inhibitor. A patient is selected as being predicted to benefit from therapeutic administration of a combination therapy of the present invention, if the level of E-cadherin expression in  
30 the patient's tumor cells is statistically similar to the control level of E-cadherin expression that has been correlated with resistance to EGFR inhibitor, or if the level of E-cadherin expression in the patient's tumor cells is statistically less than or reduced from the level of E-cadherin expression that has been correlated with sensitivity to EGFR inhibitor.

In another alternate or additional method of the invention, the level of a component of TF8, preferably ZEB1, expression in the tumor cell sample may be compared to a control level of a TF8 component's expression selected from: (i) a control level that has been correlated with sensitivity to EGFR inhibitor; and (ii) a control level that has been correlated with resistance to EGFR inhibitor. A patient is selected as being predicted to benefit from therapeutic administration of a combination therapy of the present invention, if the level of a TF8 component's expression in the patient's tumor cells is statistically similar to the control level of a TF8 component's expression that has been correlated with resistance to EGFR inhibitor, or if the level of a TF8 component's expression in the patient's tumor cells is statistically greater than or enhanced from the level of a TF8 component's expression that has been correlated with sensitivity to EGFR inhibitor.

More specifically, according to the present invention, a "control level" is a control level of gene amplification and/or polysomy, and/or gene transcription or translation, which can include a level that is correlated with sensitivity to EGFR inhibitor or a level that is correlated with resistance to EGFR inhibitor. Therefore, it can be determined, based on the control or baseline level of gene amplification and/or polysomy, whether a patient sample is more likely to be sensitive to or resistant to EGFR inhibitor therapy. In one embodiment, patients are classified into six categories with ascending number of copies per cell: (1) Disomy ( $\leq 2$  copies of both targets in  $>90\%$  of cells); (2) Low trisomy ( $\leq 2$  copies of the gene in  $\geq 40\%$  of cells and 3 copies in 10-40% of the cells); (3) High trisomy ( $\leq 2$  copies of the gene in  $\geq 40\%$  of cells and 3 copies in  $\geq 40\%$  of cells); (4) Low polysomy ( $\geq 4$  copies of the gene in 10-40% of cells); (5) High polysomy ( $\geq 4$  copies of the gene in  $\geq 40\%$  of cells); and (6) Gene Amplification (GA), defined by presence of tight EGFR gene clusters and a ratio gene/chromosome per cell  $\geq 2$ , or an average of  $\geq 15$  copies of EGFR per cell in  $\geq 10\%$  of analyzed cells. The present inventors have found that patients with high gene copy numbers or a gain in copy numbers (*e.g.*, gene amplification and/or polysomy including high trisomy, low polysomy or high polysomy) of EGFR and/or HER2 are more likely to have a higher response rate to EGFR inhibitor therapy, a lower rate of progressive disease, a longer time to progression, and a higher rate of long term survivors. The higher the polysomy or overall gain in gene copy number, the better the predicted outcome. The present inventors found that the presence of HER2 gene amplification and/or polysomy in patient tumor cells confers a more sensitive phenotype to EGFR positive

patients (*e.g.*, patients showing a gain in EGFR gene copy numbers) and a better outcome to EGFR negative patients (*e.g.*, patients having no or low gain in EGFR gene copy numbers).

The method for establishing a control level of gene amplification, polysomy and/or gene transcription or translation, is selected based on the sample type, the tissue or organ from which the sample is obtained, and the status of the patient to be evaluated. Preferably, the method is the same method that will be used to evaluate the sample in the patient. In a preferred embodiment, the control level is established using the same cell type as the cell to be evaluated. In a preferred embodiment, the control level is established from control samples that are from patients or cell lines known to be resistant or sensitive to EGFR inhibitor. In one aspect, the control samples were obtained from a population of matched individuals. According to the present invention, the phrase "matched individuals" refers to a matching of the control individuals on the basis of one or more characteristics which are suitable for the type of cell or tumor growth to be evaluated. For example, control individuals can be matched with the patient to be evaluated on the basis of gender, age, race, or any relevant biological or sociological factor that may affect the baseline of the control individuals and the patient (*e.g.*, preexisting conditions, consumption of particular substances, levels of other biological or physiological factors). To establish a control level, samples from a number of matched individuals are obtained and evaluated in the same manner as for the test samples. The number of matched individuals from whom control samples must be obtained to establish a suitable control level (*e.g.*, a population) can be determined by those of skill in the art, but should be statistically appropriate to establish a suitable baseline for comparison with the patient to be evaluated (*i.e.*, the test patient). The values obtained from the control samples are statistically processed using any suitable method of statistical analysis to establish a suitable baseline level using methods standard in the art for establishing such values.

It will be appreciated by those of skill in the art that a control level need not be established for each assay as the assay is performed but rather, a baseline or control can be established by referring to a form of stored information regarding a previously determined control level for sensitive and resistant patients (responders and non-responders), such as a control level established by any of the above-described methods. Such a form of stored information can include, for example, but is not limited to, a reference chart, listing or electronic file of population or individual data regarding sensitive and resistant

tumors/patients, or any other source of data regarding control level gene amplification or polysomy that is useful for the patient to be evaluated.

The method of the present invention includes the use of EGFR inhibitors, HDAC inhibitors, or an agonist thereof, or a drug having substantially similar biological activity as the EGFR inhibitor or HDAC inhibitor. An agonist, as used herein, is a compound that is characterized by the ability to agonize (e.g., stimulate, induce, increase, enhance, or mimic) the biological activity of a naturally occurring or reference protein or compound. More particularly, an agonist can include, but is not limited to, a compound, protein, peptide, or nucleic acid that mimics or enhances the activity of the natural or reference compound, and includes any homologue, mimetic, or any suitable product of drug/compound/peptide design or selection which is characterized by its ability to agonize (e.g., stimulate, induce, increase, enhance) the biological activity of a naturally occurring or reference compound. In contrast, an antagonist refers to any compound which inhibits (e.g., antagonizes, reduces, decreases, blocks, reverses, or alters) the effect of a naturally occurring or reference compound as described above. More particularly, an antagonist is capable of acting in a manner relative to the activity of the reference compound, such that the biological activity of the natural or reference compound, is decreased in a manner that is antagonistic (e.g., against, a reversal of, contrary to) to the natural action of the reference compound. Such antagonists can include, but are not limited to, any compound, protein, peptide, or nucleic acid (including ribozymes and antisense) or product of drug/compound/peptide design or selection that provides the antagonistic effect.

Agonists and antagonists that are products of drug design can be produced using various methods known in the art. Various methods of drug design, useful to design mimetics or other compounds useful in the present invention are disclosed in Maulik et al., 1997, *Molecular Biotechnology: Therapeutic Applications and Strategies*, Wiley-Liss, Inc., which is incorporated herein by reference in its entirety. An agonist or antagonist can be obtained, for example, from molecular diversity strategies (a combination of related strategies allowing the rapid construction of large, chemically diverse molecule libraries), libraries of natural or synthetic compounds, in particular from chemical or combinatorial libraries (i.e., libraries of compounds that differ in sequence or size but that have the similar building blocks) or by rational, directed or random drug design. See for example, Maulik et al., *supra*.



In a molecular diversity strategy, large compound libraries are synthesized, for example, from peptides, oligonucleotides, natural or synthetic steroidal compounds, carbohydrates and/or natural or synthetic organic and non-steroidal molecules, using biological, enzymatic and/or chemical approaches. The critical parameters in developing a molecular diversity strategy include subunit diversity, molecular size, and library diversity. The general goal of screening such libraries is to utilize sequential application of combinatorial selection to obtain high-affinity ligands for a desired target, and then to optimize the lead molecules by either random or directed design strategies. Methods of molecular diversity are described in detail in Maulik, et al., *ibid*.

A drug having substantially similar biological activity as an HDAC inhibitor or an EGFR inhibitor described herein refers to a drug having substantially any function(s) exhibited or performed by the reference compound that is ascribed to the reference compound as measured or observed *in vivo* (*i.e.*, under physiological conditions) or *in vitro* (*i.e.*, under laboratory conditions).

Another embodiment of the invention includes an assay kit comprising: (a) a means for detecting a level of a biomarker or a combination of biomarkers selected from: a level of expression of E-cadherin; and/or a level of expression of a component of TF8, preferably ZEB1; and (b) information containing a predetermined control level of E-cadherin transcripts and/or protein; and/or information containing a predetermined control level of a component of TF8 transcripts and/or protein, preferably ZEB1. The kit can further include a means for detecting a level of a biomarker or combination of biomarkers selected from: (i) a level of amplification of the epidermal growth factor receptor (EGFR) gene; (ii) a level of polysomy of the EGFR gene; (iii) a level of amplification of the human tyrosine kinase receptor-type receptor (HER2) gene; (iv) a level of polysomy of the HER2 gene; (v) a level of EGFR protein expression; (vi) a level of phosphorylated Akt protein expression. Appropriate controls would also be included.

In one embodiment, a means for detecting E-cadherin, or a component of TF8, or for detecting EGFR or HER2 genes or proteins or other biomarkers, can generally be any type of reagent that can be used in a method of the present invention. Such a means for detecting include, but are not limited to: a probe that hybridizes under stringent hybridization conditions to a gene (*e.g.*, an EGFR gene), antibodies reactive to E-cadherin peptides or a component of TF8 peptides, and labeled probes that hybridize to E-cadherin transcripts or a component of TF8 RNA transcripts. Nucleic acid sequences and protein sequences for

these genes and proteins are known in the art and can be used to produce such reagents for detection.

The means for detecting of the assay kit of the present invention can be conjugated to a detectable tag or detectable label. Such a tag can be any suitable tag which allows for  
5 detection of the reagents used to detect the gene of interest and includes, but is not limited to, any composition or label detectable by spectroscopic, photochemical, electrical, optical or chemical means. Useful labels in the present invention include fluorescent dyes (e.g., fluorescein, texas red, rhodamine, green fluorescent protein, and the like), radiolabels (e.g.,  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ ), and colorimetric labels.

10 In addition, the means for detecting of the assay kit of the present invention can be immobilized on a substrate. Such a substrate can include any suitable substrate for immobilization of a detection reagent such as would be used in any of the previously described methods of detection. Briefly, a substrate suitable for immobilization of a means for detecting includes any solid support, such as any solid organic, biopolymer or inorganic  
15 support that can form a bond with the means for detecting without significantly effecting the activity and/or ability of the detection means to detect the desired target molecule. Exemplary organic solid supports include polymers such as polystyrene, nylon, phenol-formaldehyde resins, and acrylic copolymers (e.g., polyacrylamide).

The kits of the invention can further include predetermined instructions for  
20 administration of the combination therapy of an EGFR inhibitor and an HDAC inhibitor of the invention, and in some embodiments, may further include doses of an EGFR inhibitor and/or an HDAC inhibitor to administer to a patient.

The Examples, which follow, are illustrative of specific embodiments of the invention, and various uses thereof. They are set forth for explanatory purposes only, and  
25 are not to be taken as limiting the invention.

### Examples

The following materials and methods were used in all Examples presented herein.

#### Materials and Methods

30 *Cell Culture, Drugs and MTS assay.* Twenty NSCLC cell lines were used: squamous (NCI-H157, HCC95, HCC15 and H441), large-cell (H460, H1299, H2126 and H1264, a derivative of H460), adeno (Calu3, A549, H2122, H1648, H520, HCC78, HCC193, H2009, HCC44 and H3255) and bronchioalveolar (H358 and H322). The NSCLC cell lines,

HCC78, H2126, HCC95, H1299, HCC193, HCC44, HCC15, H2009 were obtained from UTSW and the H3255 was a gift from Dr. Bruce Johnson. All lines were cultured in RPMI medium 1640 under standard conditions. Gefitinib was a gift of AstraZeneca, MS-275 was a gift from Nihon Schering K.K. Stock solutions were prepared in dimethyl sulfoxide and stored at  $-20^{\circ}\text{C}$ . The drugs were diluted in fresh media before each experiment, and the final dimethyl sulfoxide concentration was  $<0.1\%$ . Epidermal growth factor (EGF) was purchased from R&D Systems Inc. (Minneapolis, MN). Growth inhibition was assessed by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium, inner salt) assay (Promega, Madison, WI). Briefly,  $2 \times 10^3$  NSCLC cells are plated in each well of 96-well flat-bottomed microtiter plates. Gefitinib was added when cell cultures became 50-80% confluent. After 4 day incubation, 50  $\mu\text{l}$  of a 2 mg/ml solution of the tetrazolium salt MTT (Promega), dissolved in RPMI 1640, is added to each well. The microtiter plates were incubated for 4 h at  $37^{\circ}\text{C}$ . The absorbency of each well is measured using an automated plate reader. The data are analyzed using a SlideWrite program to determine the  $\text{IC}_{50}$  of the drug. Cell Lysis and Western Blots and immunohistochemistry. Cells were disrupted in lysis buffer (10 mM Tris-HCl, pH 7.5/150 mM NaCl/0.5% IGEPAL/0.5 mM PMSF/10  $\mu\text{g/ml}$  leupeptin/5  $\mu\text{g/ml}$  pepstatin A/2.1  $\mu\text{g/ml}$  aprotinin) on ice. After sonication, the Bradford assay was used for protein quantification. Protein lysates (30-50  $\mu\text{g}$ ) were separated by gel electrophoresis on 7.5%-10% polyacrylamide and analyzed by Western blot using PVDF membranes (Bio-Rad Laboratories, Inc., Richmond, CA). Anti-EGFR and the phospho-specific EGFR (pY1068), (Cell Signaling, Beverly, MA) were used at 1:1,000. E-cad and  $\beta$  Actin antibodies (BD Biosciences Pharmingen/Transduction Laboratories, San Jose, CA; Sigma-Aldrich, #A5316, Saint Louis, MS) were used at 1:3,000, 1:5000 dilutions, respectively. Detection used horseradish peroxidase-conjugated secondary antibodies and chemiluminescence (Amersham Biosciences, Inc.). The anti-E-cad antibody reacting with the cytoplasmic domain of the molecule (mouse monoclonal, clone 36, Transduction Laboratories, Lexington, KY) was applied at 1/100 dilution to sectioned paraffin-embedded cell lines. Antigen retrieval was performed in citrate buffer using a Biocare Medical (Walnut Creek, CA) decloaking chamber. Peroxide blocking was performed with 3% peroxide in absolute methanol. Blocking was performed with Powerblock (Biogenics, San Ramon, CA) or avidin/biotin block. After incubation of primary antibodies for 1 hour at  $37^{\circ}\text{C}$  the secondary antibody (Dako Biotinylated Multi-Link antimouse, immunoglobulin with 40% human serum) was

applied for 30 minutes at room temperature. This was followed by application of streptavidin horseradish peroxidase enzyme complex and diaminobenzidine chromogen. The slides were then counterstained in hematoxylin and covered with a coverslip.

*RNA, Primers, and Quantitative Real-Time RT-PCR.* Total RNA was prepared from NSCLC cell lines using the RNeasy (Qiagen). During the preparation all samples were treated with RNase-free DNase 1 (10 mg/ml, Qiagen) prior to cDNA synthesis. cDNA was synthesized as part of the RT-PCR reaction from 0.3 mg total RNA. Quantitative Real-Time RT-PCR assays were performed using the SYBR Green RT-PCR Kit (Qiagen) using a GeneAmp 5700 Sequence Detector (Applied Biosystems), which allows amplification and detection (by fluorescence) in the same tube, using a kinetic approach. Amplification data were analyzed by using GENEAMP 5700 SDS software, converted into cycle numbers at a set cycle threshold (Ct values) and quantified in relation to a standard. Human adult-lung (Clontech Lab. Inc) or human fetal-lung RNA (Stratagene) was used as standards in all the experiments. Standards were used at 20, 100, 500 mg. In each experiment a no-template control and was used as controls. To normalize for the amount of input cDNA, the quantified relative amount of the generated product was divided by the amount generated for the housekeeping gene beta-Actin. All samples were performed in triplicates.

*Cell Cycle Analysis.* NSCLC Cells were plated at a density of  $0.5 \times 10^6$  cells/well in 6 well plates. Gefitinib was added to the medium after 24 hours, and the cells were incubated for another 72 hours, after which the cells were analyzed as described previously. The percentage of apoptosis was estimated from the sub-G<sub>1</sub> cell fraction.

#### Example 1

The following example describes E-cad expression in gefitinib-sensitive and gefitinib-resistant NSCLC cell lines.

A set of 21 NSCLC and one uterine cell line using the MTT assay were analyzed for their growth inhibition by gefitinib. Of the 21 NSCLC, six cell lines H3255, H358, H322, Calu3, H1648, HCC78 had IC<sub>50</sub> of <1  $\mu$ M, whereas six cell lines HCC15, H157, H460, H520, and H1264 (a duplicate cell line of H460) had IC<sub>50</sub> of  $\geq 10$   $\mu$ M. This diverse growth response to gefitinib was used to identify genes differentially expressed in this set of cell lines.

Using real-time RT-PCR, a positive correlation was detected between the expression of E-cad and sensitivity to gefitinib ( $r=0.76$ ,  $p<0.0001$ ). The highest E-cad expression was detected in the most sensitive cell line, H3255 (IC<sub>50</sub> = 0.015 $\mu$ M) that harbors the EGFR

mutation L858R. This positive correlation was detected in E-cad expression in microarrays developed from the 20 cell lines ( $r=0.74$ ,  $p=0.0002$ ). At the protein level, expression of E-cad was evaluated in 11 NSCLC cell lines western blot analysis. As shown previously, there was no correlation between EGFR expression and sensitivity to gefitinib. However, there was 100% correlation between presence or absence of E-cad expression and sensitivity or resistance to gefitinib, respectively.

Using immunohistochemistry, the expression of E-cadherin was also evaluated in two cell lines sensitive to (A431 and Calu3), and two cell lines resistant to gefitinib (H520 and H157). In the sensitive cell lines, strong expression of E-cad was detected with membranous and cytoplasmic localization, whereas expression was absent in the two resistant cell lines.

### Example 2

The following example describes the expression of E-cad regulatory molecules in NSCLC cell lines.

It is known that there is involvement of the Wnt pathway in regulating E-cad expression. The expression of molecules in the Wnt/E-cad pathway (Wnt1, Wnt5A, Wnt5B, Wnt6, Wnt7A, frizzled, axin1, disheveled, GSK3,  $\alpha$ -catenin,  $\beta$ -catenin,  $\gamma$ -catenin and E-cad) were screened in the Affimetrix data of microarrays of cell lines with  $IC_{50} < 1 \mu M$  (H3255, H358, H322, Calu3, H1648, HCC78) and with  $IC_{50} > 10 \mu M$  (H157, H520, H460 and H1264). E-cad had the highest fold upregulation in the sensitive cell lines compared to the resistant cell lines (200 fold). None of the other molecules in the wnt pathway had similar differential expression between the sensitive and resistant cell lines.

E-cad regulation involves four zinc finger transcription factors TF-8, slug, snail and SIP1. Evaluation of the cell lines microarray data revealed that TF-8 had the highest difference in expression between the sensitive and resistant cell lines (10.4 fold) compared to the other three molecules, SIP1, snail, and slug.

The expression of TF-8 was confirmed using RT-PCR. A negative correlation was detected between TF-8 expression and sensitivity to gefitinib in the 20 NSCLC cell lines ( $r=-0.74$ ,  $p=0.0002$ ). This negative correlation between TF-8 expression and gefitinib-sensitivity was detected in microarrays developed from the 20 cell lines ( $r=0.71$ ,  $p=0.0004$ ).

### Example 3

The following example describes the effect of E-cadherin on gefitinib induced apoptosis in NSCLC cell lines.

The effect of gefitinib on inducing apoptosis and cell death in NSCLC cell lines sensitive and resistant to gefitinib was evaluated. When cell lines were treated with 10  $\mu$ M of gefitinib a 35 fold increase in apoptosis and cell death was detected in the most sensitive cell line H3255. At the same concentration there was a 2.3-3.4 fold increase in apoptosis and cell death in the less sensitive cell lines (H322, H358 and Calu3), whereas, no apoptotic or necrotic effect was detected in the more resistant cell lines (H460, H520, H157 and A549).

The effect of E-cad on NSCLC cell lines apoptotic response to gefitinib was assessed by transfecting a gefitinib-resistant cell line, H157, with an E-cad-encoding adenovirus. This cell line was selected for its lack expression of E-cad, the presence of EGFR and its resistance to gefitinib. The H157 cell line was transfected with E-cad and two stable transfected lines were developed, H157-E-cad-3 and H157-E-cad-8. H157 cell line transfected with a GFP construct was used as control. Expression of E-cad was verified by western blot. Higher expression of E-cad was detected in the H157-E-cad-3 cell line compared to the H157-E-cad-8 cell line. Previous studies indicated the interaction between EGFR and E-cad. We evaluated the effect of the ectopic expression of E-cad on EGFR phosphorylation and response to EGF. Ectopic expression of E-cad did not lead to EGFR activation (phosphorylation). However, two fold increase in phosphorylation was detected in transfected cell lines treated with EGF.

The effect of the ectopic expression of E-cad on cell survival was evaluated. Three and nine fold increased in ratio of apoptotic to viable cells was detected in both the cell lines, H157-Ecad-8 and H157-Ecad-3 (8.8:87.8% to 21:69% and 43.5:48.4%, respectively) as compared to the control cell line H157-GFP. Response to gefitinib was further enhanced. Cell lines were treated with 10  $\mu$ M of gefitinib for 48 hours and apoptosis and necrosis was evaluated using annexin V and propidium iodine. Six and thirteen fold increase in ratio apoptotic to viable cells (8.4:87.4% to 31.5:55.3%; 8.4:87.4 to 49.8:37.8%, respectively) and three to nine fold increase ratio necrotic to viable cells (11.5:88.1 to 26.1:70.6; 11.5:88.1 to 52.9:45.8) was detected in the H157-E-cad-3 and H157-E-cad-8 cell line compared to the control cell line H157-GFP when treated with gefitinib.

These data indicate that restoring E-cad expression lead to an increase in apoptosis and it restores the effect of gefitinib on cell lines resistant to gefitinib.

#### Example 4

The following example shows that histone deacetylase HDAC inhibitors reverse resistance to gefitinib.

It is known that E-cadherin expression is restored in NSCLC by inhibiting HDAC with TSA. The inventors determined whether pretreatment of NSCLC cell lines with HDACi will lead to changes in gene and protein expression and improve sensitivity to gefitinib. The IC of MS-275 was evaluated in the gefitinib-resistant NSCLC cell lines H157, H520, and H460. The IC<sub>25-75</sub> in these cell lines was detected between 0.5 and 4  $\mu$ M. Expression of E-cad was evaluated in these cell lines. Eight to twelve fold upregulation of E-cad expression was detected all the cell lines tested 24 hours after treatment with 4 or 10  $\mu$ M MS-275. Next the inventors evaluated the effect of pretreatment of the NSCLC lung cancer cell lines with MS-275 on their response to gefitinib. The NSCLC cell lines H157, H520, H460, and H1703 were treated with the HDAC inhibitor, MS-275 alone, with gefitinib alone or with MS-275, 24 hours prior to treatment with gefitinib. A synergistic effect was detected by the sequential use of MS-275 followed by gefitinib in these cell lines. Increasing doses of MS-275 are used. Cell death was several folds higher when cell lines when cell lines were treated sequentially with the two drugs, compared to treatment with each drug alone. See Fig. 2, showing the effect of treatment with either gefitinib alone or with combination therapy of gefitinib and MS-275, on H175 cells' adjusted ratio of apoptotic and necrotic cells to viable cells.

Each reference cited herein is incorporated by reference in its entirety.

#### References

Jemal et al., *CA Cancer J Clin.* 54(1):8-29, 2004.

Parkin, *The Lancet Oncology* 2:533-543, 2001.

Hirsch et al., *Cancer* 41 Suppl 1:S29-42, 2003.

Arteaga., *Exp Cell Res* 284:122-130, 2003.

Yarden and Sliwkowski, *Nat Rev Mol Cell Biol.* 2:127-137, 2001.

Jorissen et al., *Exp Cell Res* 284:31-53, 2003.

Levitzki and Gazit, *Science* 267:1782-8, 1995.

Fukuoka et al., *J Clin Oncol.* 21:2237-2246, 2003.

Kris et al., *J. Am. Med. Assoc.* 290, 2149-2158, 2003.

Perez-Soler et al., *Proc. Am. Soc. Clin. Oncol.*, 20: 310a (1235) 2001.

Shepherd et al., *Journal of Clinical Oncology*, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7022.

- Lynch et al., *N Engl J Med* 350:2129-39, 2004.
- Paez et al., *Science* (Wash DC) 304:1497-500, 2004.
- Pao et al., *Proc Natl Acad Sci U S A* 101(36):13306-11, 2004.
- Cappuzzo et al., *J Natl Cancer Inst* 96:2004.
- 5 Reginato et al., *Nat Cell Biol.* 5(8):733-40, 2003.
- Dumstrei et al., *Development*;129(17):3983-94, 2002.
- Al Moustafa et al., *Lung Cancer.* 37:49-56, 2002.
- Qian et al., *EMBO J.* 23:1739-84, 2004.
- Pece et al., *J Biol Chem* 274(27):19347-51, 1999.
- 10 Pece and Gutkind, *J Biol Chem.* 275(52):41227-33, 2000.
- Bremnes et al., *J Clin Oncol.* 20:2417-2428, 2002.
- Kintner, *Cell* 69: 225-236, 1992.
- Jiang, *Br J Surg* 83: 437-446, 1996.
- Ohira et al., *Proc Natl Acad Sci U S A.* 100:10429-10434, 2003.
- 15 Conacci-Sorrell et al., *J Cell Biol.* 163(4):847-57, 2003.
- Lu et al., *Cancer Cell.* 4(6):499-515, 2003.
- Batsche et al., *Mol Cell Biol.* 18(7):3647-58,1998.
- Bolos et al., *J. Cell Sci.* 116:499-511, 2003.
- van Grunsven et al., *J Biol Chem.* 278:26135-26145, 2003.
- 20 Comijn et al., *Mol Cell* ;7(6):1267-78, 2001.
- Verschueren et al., *J Biol Chem.* 274:20489-98, 1999.
- Sekido et al., *Mol Cell Biol.* 14:5692-700, 1994.
- Cano et al., *Nat. Cell Biol.* 2:76-83, 2000.
- Hajra et al., *Cancer Res.* 62:1613-1618, 2002.
- 25 Chinnadurai, *Mol. Cell* 9, 213-224, 2002.
- Postigo and Dean, *Proc. Natl. Acad. Sci. USA* 96, pp. 6683-6688, 1999.
- de Ruijter et al., *Biochem J.*370:737-749, 2003.
- Marks et al., *J Natl Cancer Inst (Bethesda)*,92:1210-6, 2000.
- Zelent et al., *Clin Cancer Res* 10: 4622-4629, 2004.
- 30 Gore et al., 2004 ASCO Annual Meeting Proceedings Vol 22, No 14S (July 15 Supplement): 3026, 2004.
- Huelsken et al., *Curr. Opin. Genet. Dev.* 11, 547-553, 2001.
- Cowley et al., *J Pathol.* 179:183-7, 1996.



Suzuki et al., *Lung Cancer*;42(1):35-41, 2003.

Cappuzzo et al., *J Clin Oncol*. 21(14):2658-63, 2003.

Fricke et al., *Oncology* 66(2):150-9, 2004.

Satoh et al., *Biocell*. 27(1):47-55, 2003.

5 Rosivatz et al., *Int J Cancer* 111(5):711-9, 2004.

Ozawa et al., *EMBO J*. 8: 1711-1717, 1989.

DiGiuseppe et al., *Leukemia* 13:1243-1253, 1999.

Chinnaiyan et al., *Journal of Clinical Oncology*, 2004 ASCO Annual Meeting  
Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement): 3029, 2004.

10

What is claimed is:

1. A method to treat a patient with cancer, comprising administering to the patient a combination of at least one histone deacetylase (HDAC) inhibitor and at least one epidermal growth factor receptor (EGFR) inhibitor.
- 5        2. The method of Claim 1, wherein the combination is administered sequentially.
3. The method of Claim 2, wherein at least a substantial portion of the HDAC inhibitor is administered before a substantial portion of the EGFR inhibitor is administered.
4. The method of Claim 2, wherein the HDAC inhibitor is MS-275 and wherein  
10 the EGFR inhibitor is gefitinib.
5. The method of Claim 4, wherein the dosing regime comprises administration of MS-275 at 2 mg/m<sup>2</sup> orally weekly for 4 weeks followed by administration of gefitinib at 250 mg orally per day for 4 weeks.
6. The method of Claim 2, wherein the combination is administered over  
15 substantially the same time period.
7. The method of Claim 6, wherein the dosing regime comprises administration of MS-275 at 2 mg/m<sup>2</sup> orally weekly for 4 weeks coadministered with gefitinib at 250 mg orally per day for 4 weeks.
8. The method of any one of the preceding claims, wherein the HDAC inhibitor  
20 is selected from the group consisting of a hydroxamic acid, a carboxylic acid, a benzamide, an epoxide, a short-chain fatty acid, a cyclic tetrapeptide containing a 2-amino-8-oxo-9, 10-epoxy-decanoyl moiety, and a cyclic peptide without the 2-amino-8-oxo-9, 10-epoxy-decanoyl moiety.
9. The method of Claim 8, wherein the hydroxamic acid is selected from the  
25 group consisting of: suberoylanilidine hydroxamic acid, TSA, and SAHA.
10. The method of Claim 8, wherein the carboxylic acid is selected from the group consisting of: butanoic acid, valproic acid, and 4-phenylbutanoic acid.
11. The method of Claim 8, wherein the benzamide is selected from the group consisting of: N-acetyldinaline and MS-275.
- 30        12. The method of Claim 8, wherein the epoxide is selected from the group consisting of: trapoxin, depeudecin, and depsipeptide FK 228.
13. The method of any one of Claims 1 to 7, wherein the HDAC inhibitor is MS-275.

14. The method of Claim 13, wherein MS-275 is administered in a dosing regime comprising administering MS-275 at 2 mg/m<sup>2</sup> orally weekly for 4 weeks or administering MS-275 4 mg/m<sup>2</sup> orally biweekly for 4 weeks.

15. The method of any one of Claims 1 to 7, wherein the EGFR inhibitor is selected from the group consisting of gefitinib, erlotinib, an agonist of gefitinib and an agonist of erlotinib.

16. The method of any one of Claims 1 to 7, wherein the EGFR inhibitor is gefitinib or erlotinib.

17. The method of Claim 16, wherein the gefitinib is administered in a dosing regime comprising administration of 250 mg PO per day and wherein the erlotinib is administered in a dosing regime comprising administration of 150 mg PO per day.

18. The method of any one of the preceding claims, wherein the cancer is an epithelial malignancy.

19. The method of any one of Claims 1 to 17, wherein the cancer is lung cancer.

20. The method of Claim 19, wherein the cancer is non-small cell lung cancer.

21. The method of any one of the preceding claims, wherein the cancer is resistant to EGFR inhibitors.

22. The method of any one of the preceding claims, wherein the cancer comprises cancerous cells having low or no gain in copy number of the EGFR gene or low or no gain in copy number of the HER2 gene, or a combination thereof, as compared to cancerous cells that are sensitive to EGFR inhibitors.

23. The method of any one of Claims 1 to 21, wherein the cancer comprises cancerous cells having reduced expression of EGFR protein as compared to cancerous cells that are sensitive to EGFR inhibitors.

24. The method of any one of Claims 1 to 23, wherein the cancer comprises cancerous cells having a reduced level of E-cadherin gene expression as compared to cancerous cells that are sensitive to EGFR inhibitors.

25. The method of any one of Claims 1 to 24, wherein the cancer comprises cancerous cells having an enhanced level of at least one component of TF8 expression as compared to cancerous cells that are sensitive to EGFR inhibitors.

26. The method of Claim 25, wherein the component comprises ZEB1.

27. A method to treat a patient with an epidermal growth factor receptor (EGFR) inhibitor-resistant cancer by sensitizing the cancer cells to EGFR inhibitors, comprising

administering to the patient a combination of at least one histone deacetylase (HDAC) inhibitor and at least one EGFR inhibitor.

28. The method of Claim 27, wherein the method additionally comprises the step of evaluating the cancer to predict resistance to an EGFR inhibitor prior to administration of the therapeutic composition.

29. The method of Claim 28, wherein the step of evaluating the cancer comprises:

a) detecting in a sample of tumor cells from a patient a level of a biomarker selected from the group consisting of:

i) a level of amplification of the epidermal growth factor receptor (EGFR) gene;

ii) a level of polysomy of the EGFR gene;

iii) a level of amplification of the human tyrosine kinase receptor-type receptor (HER2) gene; and

iv) a level of polysomy of the HER2 gene;

b) comparing the level of the biomarker in the tumor cell sample to a control level of the biomarker selected from the group consisting of:

i) a control level of the biomarker that has been correlated with sensitivity to the EGFR inhibitor; and

ii) a control level of the biomarker that has been correlated with resistance to the EGFR inhibitor; and

c) selecting the patient as being predicted to not benefit from therapeutic administration of the EGFR inhibitor, or being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of the biomarker in the patient's tumor cells is statistically less than the control level of the biomarker that has been correlated with sensitivity to the EGFR inhibitor, or if the level of the biomarker in the patient's tumor cells is statistically similar to or less than the level of the biomarker that has been correlated with resistance to the EGFR inhibitor.

30. The method of Claim 28, further comprising:

a) detecting a level of expression of epidermal growth factor receptor (EGFR) protein in the tumor cell sample;

b) comparing the level of EGFR protein expression in the tumor cell sample to a control level of EGFR protein expression selected from the group consisting of:

i) a control level that has been correlated with sensitivity to the EGFR inhibitor; and

ii) a control level that has been correlated with resistance to the EGFR inhibitor; and

c) selecting the patient as being predicted to not benefit from therapeutic administration of the EGFR inhibitor, or being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of EGFR protein expression in the patient's tumor cells is statistically less than the control level of EGFR protein expression that has been correlated with sensitivity to the EGFR inhibitor, or if the level of EGFR protein expression in the patient's tumor cells is statistically similar to or less than the level of EGFR protein expression that has been correlated with resistance to the EGFR inhibitor.

31. The method of Claim 29, further comprising the steps of:

d) detecting in the sample of tumor cells a level of expression of the E-cadherin protein;

e) comparing the level of E-cadherin expression in the tumor cell sample to a control level of E-cadherin expression selected from the group consisting of:

i) a control level that has been correlated with sensitivity to an EGFR inhibitor; and

ii) a control level that has been correlated with resistance to an EGFR inhibitor; and

f) selecting the patient as being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of E-cadherin expression in the patient's tumor cells is statistically reduced compared to the control level of E-cadherin expression that has been correlated with sensitivity to an EGFR inhibitor, or if the level of E-cadherin expression in the patient's tumor cells is statistically similar than the level of E-cadherin expression that has been correlated with resistance to an EGFR inhibitor.

32. The method of Claim 29, further comprising the steps of:

d) detecting in the sample of tumor cells a level of expression of at least one component of TF8;

e) comparing the level of expression of at least one component of TF8 in the tumor cell sample to a control level of expression of at least one component of TF8 selected from the group consisting of:

i) a control level that has been correlated with sensitivity to an EGFR inhibitor; and

ii) a control level that has been correlated with resistance to an EGFR inhibitor; and

f) selecting the patient as being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of expression of at least one component of TF8 in the patient's tumor cells is statistically increased compared to the control level of expression of at least one component of TF8 that has been correlated with sensitivity to an EGFR inhibitor, or if the level of expression of at least one component of TF8 in the patient's tumor cells is statistically similar than the level of expression of at least one component of TF8 that has been correlated with resistance to an EGFR inhibitor.

33. A method to select a cancer patient who is predicted to benefit from therapeutic administration of a combination of at least one histone deacetylase (HDAC) inhibitor and at least one epidermal growth factor receptor (EGFR) inhibitor, comprising:

a) detecting in the sample of tumor cells a level of expression of the E-cadherin protein;

b) comparing the level of E-cadherin expression in the tumor cell sample to a control level of E-cadherin expression selected from the group consisting of:

i) a control level that has been correlated with sensitivity to an EGFR inhibitor; and

ii) a control level that has been correlated with resistance to an EGFR inhibitor; and

c) selecting the patient as being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of E-cadherin expression in the patient's tumor cells is statistically reduced compared to the control level of E-cadherin expression that has been correlated with sensitivity to an EGFR

inhibitor, or if the level of E-cadherin expression in the patient's tumor cells is statistically similar than the level of E-cadherin expression that has been correlated with resistance to an EGFR inhibitor.

34. A method to select a cancer patient who is predicted to benefit from therapeutic administration of a combination of at least one histone deacetylase (HDAC) inhibitor and at least one epidermal growth factor receptor (EGFR) inhibitor, comprising:

a) detecting in the sample of tumor cells a level of amplification of zinc finger transcription factor genes;

b) comparing the level of amplification of zinc finger transcription factor genes in the tumor cell sample to a control level of amplification of zinc finger transcription factor genes selected from the group consisting of:

i) a control level that has been correlated with sensitivity to an EGFR inhibitor; and

ii) a control level that has been correlated with resistance to an EGFR inhibitor; and

c) selecting the patient as being predicted to benefit from the combination of HDAC inhibitor and EGFR inhibitor, if the level of amplification of zinc finger transcription factor genes in the patient's tumor cells is statistically greater compared to the control level of amplification of zinc finger transcription factor genes that has been correlated with sensitivity to EGFR inhibitors, or if the level of amplification of zinc finger transcription factor genes in the patient's tumor cells is statistically similar than the level of amplification of zinc finger transcription factor genes that has been correlated with resistance to EGFR inhibitors.

35. A method to treat a patient with a cancer that is resistant to at least one epidermal growth factor receptor (EGFR) inhibitor, comprising administering to the patient a combination of at least one histone deacetylase (HDAC) inhibitor and at least one epidermal growth factor receptor (EGFR) inhibitor, wherein the cancer is an epithelial malignancy.




FIG. 1B




FIG. 1A






FIG. 2